title: [Ovarian hyperstimulation syndrome: pathophysiology, risk factors, prevention, diagnosis and treatment].
abstract: The ovarian hyperstimulation syndrome is a major complication of ovulation induction for in vitro fertilization, with severe morbidity and possible mortality. Whereas its pathophysiology remains ill-established, the VEGF may play a key role as well as coagulation disturbances. Risk factors for severe OHSS may be related to patients characteristics or to the management of the ovarian stimulation. Two types of OHSS are usually distinguished: the early OHSS, immediately following the ovulation triggering and a later and more severe one, occurring in case of pregnancy. As no etiologic treatment is available, the therapeutic management of OHSS should focus on its related-complications. Thrombotic complications that can occur in venous or arterial vessels represent the major risk of OHSS, possibly conducting to myocardial infarction and cerebrovascular accidents. Once the OHSS is diagnosed, prevention of thrombotic accidents remains the major issue.
authors.affiliation: Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Antoine-Béclère, AP-HP, 157, rue de la Porte-de-Trivaux, 92141 Clamart, France. frederic.lamazou@abc.aphp.fr
authors.forename: F
authors.initials: F
authors.lastname: Lamazou
authors.forename: A
authors.initials: A
authors.lastname: Legouez
authors.forename: V
authors.initials: V
authors.lastname: Letouzey
authors.forename: M
authors.initials: M
authors.lastname: Grynberg
authors.forename: X
authors.initials: X
authors.lastname: Deffieux
authors.forename: C
authors.initials: C
authors.lastname: Trichot
authors.forename: H
authors.initials: H
authors.lastname: Fernandez
authors.forename: R
authors.initials: R
authors.lastname: Frydman
mesh_terms: D054304:Anti-Mullerian Hormone / Q000032:analysis; D006063:Chorionic Gonadotropin / Q000009:adverse effects; D004958:Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D015994:Incidence; D007378:Interleukins / Q000032:analysis; D007986:Luteinizing Hormone / Q000009:adverse effects; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D016471:Ovarian Hyperstimulation Syndrome / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*; D010062:Ovulation Induction / Q000009:adverse effects; D011247:Pregnancy; D012084:Renin-Angiotensin System / Q000502:physiology; D012307:Risk Factors; D012720:Severity of Illness Index; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D042442:Vascular Endothelial Growth Factors / Q000502:physiology
chemical_list: D006063:Chorionic Gonadotropin; D007378:Interleukins; D042442:Vascular Endothelial Growth Factors; D004958:Estradiol; D054304:Anti-Mullerian Hormone; D007986:Luteinizing Hormone